Christopher G. Bunick

1 week ago | dermatologytimes.com | Emma Andrus |Christopher G. Bunick

In an interview with Dermatology Times, Christopher Bunick, MD, PhD, associate professor of dermatology and translational biomedicine at Yale University School of Medicine, offered perspective on where investigational biologics targeting the OX40 and OX40 ligand (OX40L) pathway may eventually fit into the already complex atopic dermatitis (AD) treatment landscape. “It’s a complicated atopic dermatitis landscape right now,” Bunick said. “We obviously have the oral JAK inhibitors.

2 weeks ago | dermatologytimes.com | Emma Andrus |Christopher G. Bunick

In a recent interview with Dermatology Times, Christopher Bunick, MD, PhD, associate professor of dermatology and translational biomedicine at Yale University School of Medicine, shared insights into the evolving science of biologics for atopic dermatitis (AD)—specifically, the emerging therapeutic potential of targeting the OX40/OX40 ligand pathway. According to Bunick, a critical limitation of current biologic therapies lies in their "monotargeted" approach.

2 weeks ago | dermatologytimes.com | Emma Andrus |Christopher G. Bunick

As clinicians look ahead to the upcoming Revolutionizing Atopic Dermatitis (RAD) conference, scheduled for June 6 to 7 in Nashville, Tennessee, one of the much-anticipated lectures is set to be delivered by Christopher Bunick, MD, PhD, associate professor of dermatology and translational biomedicine at Yale University School of Medicine and Dermatology Times' 2025 editor in chief.

2 months ago | dermatologytimes.com | Kaitlyn Bader |Christopher G. Bunick

“When it comes to oral antibiotics, one of the topics I focused on is the fact that antibiotic stewardship is needed. I also like to say that we are honorary gastroenterologists in dermatology because the antibiotics we prescribe affect the gut. We know that the gut microbiome is so important to human health,” said Christopher Bunick, MD, PhD, in an interview at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida.

2 months ago | dermatologytimes.com | Kaitlyn Bader |Christopher G. Bunick

“We have benzoyl peroxide products that are forming benzene, some of them at levels above the conditional limit and are not lasting to the point of the expiration date on the product. This is a regulatory problem. These products are not in line with the FDA regulatory standard, and this is an opportunity for innovation in dermatology,” said Christopher Bunick, MD, PhD, in an interview at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida.